PARP1 and ovarian neoplasm: BRCA-deficient cancer cells cannot repair DSBs accumulated by PARP inhibition and thus undergo apoptosis.104 Several PARP inhibitors such as olaparib, rucaparib, niraparib, and talazoparib are FDA-approved to treat multiple cancers including BRCA-deficient breast and ovarian tumors.